لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

عنوان ترانسليتريتد: Garantir l’accès et la sécurité d’utilisation de la dexaméthasone pour les patients atteints de myélome multiple.

المؤلفون: Slimano F; CHU de Reims, université de Reims Champagne-Ardenne, BioSpecT, pharmacie, 51100 Reims, France; Société française de pharmacie oncologique (SFPO), Paris, France., Tournamille JF; Institut Bergonié, pharmacie, 33000 Bordeaux, France; Société française de pharmacie oncologique (SFPO), Paris, France., Bardin C; AP-HP, hôpital Cochin, service de pharmacie clinique, 75014 Paris, France; Société française de pharmacie oncologique (SFPO), Paris, France., Madelaine I; AP-HP, hôpital Saint-Louis, pharmacie, 75000 Paris, France; Société française de pharmacie oncologique (SFPO), Paris, France., Hulin C; CHU de Bordeaux, service d'hématologie et de thérapie cellulaire, Bordeaux, France; Intergroupe francophone du myélome (IFM), Paris, France., Moreau P; CHU Hôtel-Dieu, Nantes université, hématologie clinique, 44000 Nantes, France; Intergroupe francophone du myélome (IFM), Paris, France., Rioufol C; Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacie, Université Lyon 1, CICLY, 69310 Pierre-Bénite, France; Société française de pharmacie oncologique (SFPO), Paris, France. Electronic address: catherine.rioufol@chu-lyon.fr.

المصدر: Bulletin du cancer [Bull Cancer] 2023 Jun; Vol. 110 (6), pp. 731-733. Date of Electronic Publication: 2023 May 22.

نوع المنشور: Letter

بيانات الدورية: Publisher: Elsevier Country of Publication: France NLM ID: 0072416 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1769-6917 (Electronic) Linking ISSN: 00074551 NLM ISO Abbreviation: Bull Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy, Humans ; Lenalidomide/therapeutic use ; Thalidomide/therapeutic use ; Dexamethasone/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/therapeutic use

المؤلفون: Pourroy B; Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique-Hôpitaux de Marseille, Marseille, France.; French Society for Oncology Pharmacy, Paris, France., Tournamille JF; French Society for Oncology Pharmacy, Paris, France., Bardin C; French Society for Oncology Pharmacy, Paris, France.; Pharmacy Department, Cochin University Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Slimano F; French Society for Oncology Pharmacy, Paris, France.; Pharmacy, Centre Hospitalier Universitaire Reims; and Faculty of Pharmacy, EA7506, Université de Reims Champagne-Ardenne, Reims, France., Chevrier R; French Society for Oncology Pharmacy, Paris, France.; Pharmacy Department, Jean Perrin Cancer Center, Clermont Ferrand, France., Rioufol C; French Society for Oncology Pharmacy, Paris, France.; Oncology Clinical Pharmacy Unit, Lyon Sud University Teaching Hospital. Hospices Civils de Lyon, Pierre-Bénite; and EMR3738, Lyon University, Lyon, France., Madelaine I; French Society for Oncology Pharmacy, Paris, France.; Pharmacy Department, Saint Louis University Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

المصدر: JCO oncology practice [JCO Oncol Pract] 2020 Nov; Vol. 16 (11), pp. e1282-e1290. Date of Electronic Publication: 2020 Jun 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101758685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2688-1535 (Electronic) Linking ISSN: 26881527 NLM ISO Abbreviation: JCO Oncol Pract Subsets: MEDLINE

مواضيع طبية MeSH: Pandemics* , COVID-19 Drug Treatment*, Neoplasms/*drug therapy , SARS-CoV-2/*pathogenicity, COVID-19/complications ; COVID-19/epidemiology ; COVID-19/virology ; Female ; France/epidemiology ; Humans ; Male ; Medical Oncology/trends ; Neoplasms/complications ; Neoplasms/epidemiology ; Neoplasms/virology ; Pharmaceutical Services ; Pharmacies/trends ; Practice Guidelines as Topic ; SARS-CoV-2/drug effects

المؤلفون: Slimano F; Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com., Baudouin A; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr., Zerbit J; Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com., Toulemonde-Deldicque A; Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com., Thomas-Schoemann A; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com., Chevrier R; Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr., Daouphars M; Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr., Madelaine I; Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr., Pourroy B; Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr., Tournamille JF; Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com., Astier A; Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com., Ranchon F; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr., Cazin JL; Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr., Bardin C; Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr., Rioufol C; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr.

المصدر: Cancer treatment reviews [Cancer Treat Rev] 2020 Aug; Vol. 88, pp. 102063. Date of Electronic Publication: 2020 Jun 23.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE

مواضيع طبية MeSH: Coronavirus Infections/*drug therapy , Coronavirus Infections/*immunology , Medical Oncology/*standards , Neoplasms/*drug therapy , Neoplasms/*immunology , Pharmacy/*standards , Pneumonia, Viral/*drug therapy , Pneumonia, Viral/*immunology, Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Betacoronavirus/isolation & purification ; COVID-19 ; Clinical Trials as Topic/methods ; Clinical Trials as Topic/standards ; Coronavirus Infections/virology ; Humans ; Medical Oncology/methods ; Neoplasms/virology ; Pandemics ; Pharmacy/methods ; Pneumonia, Viral/virology ; Practice Guidelines as Topic ; SARS-CoV-2

المؤلفون: Barin-Le Guellec C; Laboratoire de Biochimie et Biologie Moléculaire, Unité de Pharmacogénétique, CHU de Tours, France; INSERM U1248-IPPRIT, Université, CHU de Limoges, France. Electronic address: chantal.barin-leguellec@univ-tours.fr., Lafay-Chebassier C; Service de Pharmacologie Clinique et Vigilances, Université, CHU de Poitiers, France; INSERM U1084-LNEC/ INSERM CIC 1402, Université, CHU de Poitiers, France., Ingrand I; Service de Pharmacologie Clinique et Vigilances, Université, CHU de Poitiers, France; Unité d'Epidémiologie et Biostatistique, Registre Général des Cancers Poitou-Charentes, INSERM CIC 1402, Université, CHU de Poitiers, France., Tournamille JF; Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, France., Boudet A; OMEDIT Région Centre, CHU de Tours, France., Lanoue MC; OMEDIT Région Centre, CHU de Tours, France., Defossez G; Unité d'Epidémiologie et Biostatistique, Registre Général des Cancers Poitou-Charentes, INSERM CIC 1402, Université, CHU de Poitiers, France., Ingrand P; Unité d'Epidémiologie et Biostatistique, Registre Général des Cancers Poitou-Charentes, INSERM CIC 1402, Université, CHU de Poitiers, France., Perault-Pochat MC; Service de Pharmacologie Clinique et Vigilances, Université, CHU de Poitiers, France; INSERM U1084-LNEC/ INSERM CIC 1402, Université, CHU de Poitiers, France., Etienne-Grimaldi MC; Centre Antoine Lacassagne, Nice, France.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Jan; Vol. 124, pp. 37-46. Date of Electronic Publication: 2019 Nov 09.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*toxicity , Capecitabine/*toxicity , Dihydrouracil Dehydrogenase (NADP)/*toxicity , Fluorouracil/*toxicity , Organoplatinum Compounds/*toxicity, Capecitabine/administration & dosage ; Female ; Fluorouracil/administration & dosage ; France ; Humans ; Male ; Medication Adherence

المؤلفون: Fargier E; Centre Hospitalier Lyon-Sud, Clinical Oncology Pharmacy Unit, Hospices Civils de Lyon, Pierre Benite, Lyon, France.; Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Université de Lyon, Lyon, France., Ranchon F; Centre Hospitalier Lyon-Sud, Clinical Oncology Pharmacy Unit, Hospices Civils de Lyon, Pierre Benite, Lyon, France.; Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Université de Lyon, Lyon, France., Huot L; Département de la Recherche Clinique et de l'Innovation, Cellule Innovation, Hospices Civils de Lyon, Lyon, France., Guerre P; Département de la Recherche Clinique et de l'Innovation, Cellule Innovation, Hospices Civils de Lyon, Lyon, France., Safar V; Centre Hospitalier Lyon-Sud, Department of Hematology, Hospices Civils de Lyon, Pierre-Bénite, Lyon, France., Dony A; Centre Hospitalier Lyon-Sud, Department of Hematology, Hospices Civils de Lyon, Pierre-Bénite, Lyon, France., Hequet N; Centre Hospitalier Lyon-Sud, Department of Hematology, Hospices Civils de Lyon, Pierre-Bénite, Lyon, France., Bachy E; Centre Hospitalier Lyon-Sud, Department of Hematology, Hospices Civils de Lyon, Pierre-Bénite, Lyon, France.; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.; INSERM 1052 CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Savouroux S; Clinical Oncology Pharmacy Unit, Centre Hospitalier Universitaire, Nantes, France., Fronteau C; Clinical Oncology Pharmacy Unit, Centre Hospitalier Universitaire, Nantes, France., Tomaré P; Clinical Oncology Pharmacy Unit, Centre Hospitalier Universitaire, Nantes, France., Tournamille JF; Clinical Oncology Pharmacy Unit, Centre Hospitalier Régional Universitaire, Tours, France., Schwiertz V; Centre Hospitalier Lyon-Sud, Clinical Oncology Pharmacy Unit, Hospices Civils de Lyon, Pierre Benite, Lyon, France., Vantard N; Centre Hospitalier Lyon-Sud, Clinical Oncology Pharmacy Unit, Hospices Civils de Lyon, Pierre Benite, Lyon, France., Le Gouill S; Department of Hematology, Centre Hospitalier Universitaire, Nantes, France., Gyan E; Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire, UMR CNRS 7292, Université François Rabelais, Tours, France., Salles G; Centre Hospitalier Lyon-Sud, Department of Hematology, Hospices Civils de Lyon, Pierre-Bénite, Lyon, France.; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.; INSERM 1052 CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Rioufol C; Centre Hospitalier Lyon-Sud, Clinical Oncology Pharmacy Unit, Hospices Civils de Lyon, Pierre Benite, Lyon, France. catherine.rioufol@chu-lyon.fr.; Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Université de Lyon, Lyon, France. catherine.rioufol@chu-lyon.fr.

المصدر: Annals of hematology [Ann Hematol] 2018 Jan; Vol. 97 (1), pp. 123-131. Date of Electronic Publication: 2017 Oct 10.

نوع المنشور: Comparative Study; Journal Article; Observational Study

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Follicular/*drug therapy , Lymphoma, Follicular/*economics , Rituximab/*administration & dosage , Rituximab/*economics, Administration, Intravenous ; Adult ; Aged ; Aged, 80 and over ; Cost-Benefit Analysis ; Cross-Sectional Studies ; Drug Costs ; Female ; France/epidemiology ; Hospitals, Teaching ; Humans ; Injections, Subcutaneous ; Lymphoma, Follicular/epidemiology ; Lymphoma, Follicular/metabolism ; Male ; Middle Aged ; Patient Preference/economics ; Patient Preference/statistics & numerical data ; Quality of Life ; Rituximab/pharmacokinetics

المؤلفون: Tixier F; Unité de Pharmacie Clinique Oncologique, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pierre-Bénite, France., Ranchon F; Unité de Pharmacie Clinique Oncologique, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pierre-Bénite, France.; EMR 3738, Université Lyon 1, Lyon, France., Iltis A; Service d'hématologie et thérapie cellulaire, Centre Hospitalier Universitaire de Tours, Tours, France., Vantard N; Unité de Pharmacie Clinique Oncologique, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pierre-Bénite, France., Schwiertz V; Unité de Pharmacie Clinique Oncologique, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pierre-Bénite, France., Bachy E; Service d'hématologie, Hospices Civils de Lyon, Groupement Hospitalier Sud, Lyon, France., Bouafia-Sauvy F; Service d'hématologie, Hospices Civils de Lyon, Groupement Hospitalier Sud, Lyon, France., Sarkozy C; Service d'hématologie, Hospices Civils de Lyon, Groupement Hospitalier Sud, Lyon, France., Tournamille JF; Unité de Biopharmacie Clinique Oncologique, Centre Hospitalier Universitaire de Tours, Tours, France., Gyan E; Service d'hématologie et thérapie cellulaire, Centre Hospitalier Universitaire de Tours, Tours, France., Salles G; Service d'hématologie, Université Lyon 1, UMR5239, Hospices Civils de Lyon, Groupement Hospitalier Sud, Lyon, France., Rioufol C; Unité de Pharmacie Clinique Oncologique, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pierre-Bénite, France.; EMR 3738, Université Lyon 1, Lyon, France.

المصدر: Hematological oncology [Hematol Oncol] 2017 Dec; Vol. 35 (4), pp. 584-590. Date of Electronic Publication: 2016 Jul 05.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Lymphoma/*drug therapy , Lymphoma/*pathology, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Humans ; Kidney Diseases/diagnosis ; Kidney Diseases/etiology ; Lymphoma/mortality ; Male ; Middle Aged ; Platinum/administration & dosage ; Recurrence ; Retrospective Studies ; Young Adult

المؤلفون: Brachet G; Université François-Rabelais de Tours, CNRS, GICC UMR 7292, CHRU de Tours, Service, d'immunologie, F-37032, Tours, France., Bruno C; Université François-Rabelais de Tours, CNRS, GICC UMR 7292, CHRU de Tours, Service de Pharmacie, F-37032, Tours, France., Boulay D; CHRU de Tours, Service de Pharmacie, F-37032, Tours, France., Tournamille JF; Université François-Rabelais de Tours, CNRS, GICC UMR 7292, CHRU de Tours, Service de Pharmacie, F-37032, Tours, France., Gyan E; Université François-Rabelais de Tours, CNRS, GICC UMR 7292, CHRU de Tours, Service d'Hématologie et Thérapie Cellulaire, F-37032, Tours, France., Viaud-Massuard MC; Université François-Rabelais de Tours, CNRS, GICC UMR 7292, F-37032, Tours, France., Respaud R; Université François-Rabelais de Tours, CNRS, GICC UMR 7292, CHRU de Tours, Service de Pharmacie, F-37032, Tours, France.

المصدر: Drug testing and analysis [Drug Test Anal] 2016 Sep; Vol. 8 (9), pp. 985-90. Date of Electronic Publication: 2015 Oct 20.

نوع المنشور: Journal Article; Validation Study

بيانات الدورية: Publisher: John Wiley & Sons Country of Publication: England NLM ID: 101483449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-7611 (Electronic) Linking ISSN: 19427603 NLM ISO Abbreviation: Drug Test Anal Subsets: MEDLINE

مواضيع طبية MeSH: Drug Contamination*, Antineoplastic Agents/*analysis , Chromatography, Reverse-Phase/*methods, Antineoplastic Agents/isolation & purification ; Chromatography, High Pressure Liquid/methods ; Humans ; Limit of Detection ; Quality Control

عنوان ترانسليتريتد: Étude impacto : analyse descriptive des pratiques de pharmacie clinique en cancérologie.

المؤلفون: Le Guen R; Pharmacie Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France. Electronic address: leguenro@gmail.com., Madelaine I; Pharmacie St-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France., Tournamille JF; Pharmacie Bretonneau, 2, boulevard Tonnelle, 37044 Tours, France., Bellanger A; Pharmacie Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France., Astier A; Pharmacie Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny 94100 Créteil, France., Braguer D; Université Aix-Marseille II, UMR 911-CRO2 faculté de médecine, 27, boulevard Jean-Moulin 13385 Marseille, France., Ollivier C; Pharmacie, CHU Caen, avenue de la Côte-de-Nacre, 14033 Caen, France., Bardin C; Pharmacie Cochin, 27, rue du Faubourg-St-Jacques, 75014 Paris, France., Lemare F; Pharmacie IGR, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Faculté de pharmacie, université Paris Descartes, 4, rue de l'Observatoire, 75006, Paris, France., Daouphars M; Pharmacie, CRLC Henri-Becquerel, rue d'Amiens, 76038 Rouen, France., Pinguet F; Pharmacie, CRLC Val-d'Aurelle-Parc Euromédecine 208, rue des Apothicaires, 34298 Montpellier, France., Latour JF; Pharmacie, centre Léon-Bérard, 28, rue Laennec, 69373 Lyon, France., Vigneron J; Pharmacie, CHU Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54000 Nancy, France., Tilleul P; Pharmacie Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France; Faculté de pharmacie, université Paris Descartes, 4, rue de l'Observatoire, 75006, Paris, France.

المصدر: Annales pharmaceutiques francaises [Ann Pharm Fr] 2015 May; Vol. 73 (3), pp. 223-8. Date of Electronic Publication: 2014 Nov 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Masson Editeur Country of Publication: France NLM ID: 2985176R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0003-4509 (Print) Linking ISSN: 00034509 NLM ISO Abbreviation: Ann Pharm Fr Subsets: MEDLINE

مواضيع طبية MeSH: Hematology* , Medical Oncology* , Pharmacists*, Pharmacy Service, Hospital/*organization & administration, Drug Prescriptions ; France ; Health Care Surveys ; Humans ; Professional Role ; Prospective Studies